Cardiovascular biomarkers: A risky business Maral OuzounianDouglas S. LeePeter P. Liu Invited Commentary 11 July 2007 Pages: 177 - 179
Cardiac syndrome X: Relation to microvascular angina and other conditions C. Noel Bairey MerzWafia EteibaSheryl F. Kelsey OriginalPaper 07 May 2007 Pages: 167 - 175
Perspectives and current strategies for dyslipidemia in women Sandra J. Lewis OriginalPaper 07 May 2007 Pages: 159 - 166
Exercise electrocardiogram testing and imaging in women Richard A. SteinNieca Goldberg OriginalPaper 07 May 2007 Pages: 153 - 158
Clinical guidelines for cardiovascular disease prevention: Should they differ by gender? Nanette K. Wenger OriginalPaper 07 May 2007 Pages: 148 - 152
Postmenopausal hormone therapy and cardiovascular disease: Making sense of the evidence Howard N. HodisWendy J. Mack OriginalPaper 07 May 2007 Pages: 138 - 147
Combating racial and ethnic disparities in cardiovascular disease: What is being done? Keith C. FerdinandAnnemarie Armani OriginalPaper 07 May 2007 Pages: 124 - 132
Comparing Caucasian and African American cardiovascular disease expression: What does epidemiologic research tell us? Herman A. Taylo JrJennifer M. JoeRobert J. Garrison OriginalPaper 07 May 2007 Pages: 118 - 123
Adherence to best practices: How do patient race and gender affect physician performance? Karol E. WatsonGregg C. Fonarow OriginalPaper 07 May 2007 Pages: 102 - 107
How current Guidelines for obesity underestimate risk in certain ethnicities and overestimate risk in others Anne E. SumnerMadia RicksBarbara A. Frempong OriginalPaper 07 May 2007 Pages: 97 - 101
Homocysteine lowering and cardiovascular events after acute myocardial infarction Karol E. Watson Clinical Trials Report 07 May 2007 Pages: 95 - 96
Blood biologic markers of stroke: Improved management, reduced cost? Alison E. Baird OriginalPaper 15 January 2008 Pages: 80 - 88
C-reactive protein and cardiovascular disease: Weighing the evidence Gordon D. O. LoweMark B. Pepys OriginalPaper 15 January 2008 Pages: 72 - 79
Lipoprotein-associated phospholipase A2: Risk marker or target of therapy? Christie M. Ballantyne OriginalPaper 15 January 2008 Pages: 66 - 71
Myeloperoxidase: A mechanistically linked biomarker for cardiovascular disease Marie-Luise BrennanStanley L. Hazen OriginalPaper 15 January 2008 Pages: 58 - 65
The effects of macronutrients on blood pressure and lipids: An overview of the DASH and OmniHeart trials Edgar R. MillerThomas P. ErlingerLawrence J. Appel OriginalPaper 15 January 2008 Pages: 46 - 51
The omega-6/omega-3 ratio and cardiovascular disease risk: Uses and abuses William S. Harris OriginalPaper 15 January 2008 Pages: 39 - 45
Intra-abdominal adiposity, inflammation, and cardiovascular risk: New insight in the global cardiometabolic risk Paolo CalabroEdward T. H. Yeh OriginalPaper 15 January 2008 Pages: 32 - 38
Dietary management of insulin resistance and the metabolic syndrome Andrea R. JosseCyril W. C. KendallDavid J. A. Jenkins OriginalPaper 15 January 2008 Pages: 24 - 31
Trans fats in cardiac and diabetes risk: An overview Walter C. WillettDariush Mozaffarian OriginalPaper 15 January 2008 Pages: 16 - 23
Plant-based dietary patterns in the control of obesity and cardiovascular risk Antonella DewellDean Ornish OriginalPaper 15 January 2008 Pages: 9 - 15
Serving the educational needs of 21st century cardiology Daniel Levy Invited Commentary 15 January 2008 Pages: 1 - 2
